Seasoned private markets executive focused on growth-stage technology and consumer investments, with operating experience in scaling revenue and go-to-market teams. Alan Gilmore is known for blending operational leadership with portfolio oversight, advising CEOs on strategic product and commercialization initiatives while leading deal sourcing and due diligence. Typical involvement spans board-level governance, capital strategy and exit preparation for venture and lower-middle market private equity transactions. Market-facing skills include investor relations, LP reporting and cross-border M&A execution.
Seasoned private markets executive focused on growth-stage technology and consumer investments, with operating experience in scaling revenue and go-to-market teams. Alan Gilmore is known for blending operational leadership with portfolio oversight, advising CEOs on strategic product and commercialization initiatives while leading deal sourcing and due diligence. Typical involvement spans board-level governance, capital strategy and exit preparation for venture and lower-middle market private equity transactions. Market-facing skills include investor relations, LP reporting and cross-border M&A execution.
Operates with an operator-investor mindset targeting growth-stage technology and consumer businesses where go-to-market scaling drives value. Prefers active, board-level involvement to align product, commercialization and capital strategy with exit planning, emphasizing revenue growth, unit economics and repeatable sales motion. Underwrites opportunities through operational due diligence, founder alignment and measurable GTM milestones, allocating capital for revenue acceleration rather than financial engineering. Time horizon is multi-year growth-to-exit, with disciplined risk controls and cross-border M&A optionality.
Operates with an operator-investor mindset targeting growth-stage technology and consumer businesses where go-to-market scaling drives value. Prefers active, board-level involvement to align product, commercialization and capital strategy with exit planning, emphasizing revenue growth, unit economics and repeatable sales motion. Underwrites opportunities through operational due diligence, founder alignment and measurable GTM milestones, allocating capital for revenue acceleration rather than financial engineering. Time horizon is multi-year growth-to-exit, with disciplined risk controls and cross-border M&A optionality.
| Trades 7843 | Longs Won 4412/7843 56% | Profit Factor 21.46 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $222,803.79 |
| Average Win $26,064.11 | Best Trade (Aug 14) $13.19M | Sharpe Ratio -12.61 |
| Average Loss -$1,561.56 | Worst Trade (Sep 01) -$1.13M | Z-Score 19.85 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 2w 6d | Expectancy $13,976.59 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 250,000 | 225,000 | 200,000 | 175,000 | 150,000 | 125,000 | 100,000 | 75,000 | 50,000 | 25,000 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
A Agilent Technologies Inc. | 108 | $12,929.42 | $14,943.96 | - | $2,014.54 | 15.58% | -0.245% |
AA Alcoa Corporation | 19 | $646 | $859.94 | - | $213.94 | 33.12% | +0.645% |
AAMI Acadian Asset Management Inc. | 60 | $1,150 | $5,189.4 | - | $4,039.4 | 351.25% | +3.026% |
AAPL Apple Inc. | 32,422 | $7.73M | $10.02M | - | $2.28M | 29.51% | -7.354% |
ABBV AbbVie Inc. | 1,170 | $194,764.89 | $293,599.8 | - | $98,834.91 | 50.75% | -2.513% |
ABCB Ameris Bancorp | 36 | $1,886.25 | $3,139.56 | - | $1,253.31 | 66.44% | -0.411% |
ABT Abbott Laboratories | 679 | $73,186.93 | $71,770.3 | - | -$1,416.63 | -1.94% | +0.085% |
ABUS Arbutus Biopharma Corporation | 242 | $605 | $1,050.28 | - | $445.28 | 73.6% | -1.587% |
ACA Arcosa Inc. | 108 | $9,137.07 | $15,681.6 | - | $6,544.53 | 71.63% | -0.021% |
ACAD Acadia Pharmaceuticals Inc. | 218 | $4,000.68 | $5,639.66 | - | $1,638.98 | 40.97% | -2.561% |
ACB Aurora Cannabis Inc. | 10 | $44 | $27.9 | - | -$16.1 | -36.59% | -1.413% |
ACGL Arch Capital Group Ltd | 190 | $18,319.85 | $19,100.7 | - | $780.85 | 4.26% | -0.603% |
ACIW ACI Worldwide, Inc. | 148 | $4,529 | $8,484.84 | - | $3,955.84 | 87.34% | -0.624% |
ACLS Axcelis Technologies, Inc. | 71 | $4,948 | $9,256.98 | - | $4,308.98 | 87.09% | +4.129% |
ACM Aecom | 9 | $763.65 | $651.51 | - | -$112.14 | -14.68% | +0.878% |
ACN Accenture plc Class A | 67 | $19,145.34 | $11,116.64 | - | -$8,028.7 | -41.94% | +1.611% |
ACR Acres Commercial Realty Corp. | 64 | $1,346.28 | $1,120 | - | -$226.28 | -16.81% | -0.794% |
ACTG Acacia Research Corporation | 435 | $1,643.27 | $1,927.05 | - | $283.78 | 17.27% | +0.454% |
ADAM Adamas Trust, Inc. | 298 | $1,806 | $2,702.86 | - | $896.86 | 49.66% | +1.454% |
ADBE Adobe Inc. | 263 | $107,820.13 | $65,857.83 | - | -$41,962.3 | -38.92% | +1.013% |